Estimated savings of up to $510 per month compared to the Zepbound pen. The vial is distributed in a one-month supply, defined as 28 days and 4 vials. Explore speed, convenience, and access to focused care with independent telehealth or in-person providers through LillyDirect.

Use Zepbound exactly as your healthcare provider says. Use Zepbound with a reduced-calorie diet and increased physical activity. Zepbound is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm. Use Zepbound 1 time each week, at any time of the day. Change (rotate) your injection site with each weekly injection.

Eli Lilly and Company has created a new self-pay pharmacy component of LillyDirect® where patients with a valid, on-label, electronic prescription from the health care provider of their choice can purchase Zepbound 2.5 and 5 mg vials.1

When initiating Zepbound, consider reducing the dose of concomitantly administered insulin or insulin secretagogues (e.g., sulfonylureas) to reduce the risk of hypoglycemia. Zepbound delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications.

Zepbound is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. Zepbound should be used with a reduced- …

Zepbound (tirzepatide) is an injectable prescription medicine that may help adults with obesity, or with excess weight (overweight) who also have weight-related medical problems, lose weight and keep it off.

Zepbound is a once-weekly injectable prescription medicine for chronic weight management in adults with an initial body mass index of at least 30 kg/m2 or at least 27 kg/m2 with at least one weight-related comorbid condition.

• Use ZEPBOUND exactly as your healthcare provider tells you to. A healthcare provider should show you how to prepare to inject your dose of ZEPBOUND before injecting the first time. • Use ZEPBOUND with a reduced-calorie diet and increased physical activity.

INDIANAPOLIS, Dec. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound ® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. 1 Zepbound may help adults with moderate-to-severe ...

Nov 8, 2023 · Zepbound is the first and only approved treatment activating two incretin hormone receptors, GIP and GLP-1, to tackle an underlying cause of excess weight.